News

Worldwide Clinical Trials and Datavant have teamed up to improve research and clinical trial design for neurodegenerative diseases like Parkinson’s disease. The collaboration will combine Worldwide’s expertise in neurodegenerative diseases and clinical trial regimens with Datavant’s experience in organizing and structuring healthcare data. It intends to study…

e-Therapeutics recently entered a collaboration agreement with C4X Discovery to identify new intervention strategies for the treatment of Parkinson’s disease. The collaboration is based on leveraging e-Therapeutics’ Network-Driven Drug Discovery (NDD) platform for drug discovery with C4X Discoveries’ Taxonomy3 technology to identify new cellular mechanisms that are important…

Dopamine-releasing neurons are important players in the formation of new, long-term memories,  research shows. These findings may help develop new therapies for memory disorders. The study “Novelty-Sensitive Dopaminergic Neurons in the Human Substantia Nigra Predict Success of Declarative Memory Formation” was published in the journal Current Biology.

The Michael J. Fox Foundation (MJFF) and the Edmond J. Safra Philanthropic Foundation recently awarded five new medical centers with funding to train clinician-researchers working with Parkinson’s disease and other movement disorders. The five centers, awarded at the fourth round of fellowship funding, will receive financial assistance through a…

New nanoparticles containing a specific part of the rabies virus may improve brain-targeting therapy in Parkinson’s patients, study suggests. The research, “Targeted Brain Delivery of Rabies Virus Glycoprotein 29-Modified Deferoxamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Mice,” was published in the journal ACS Nano. A common feature…